Kouichi Tanonaka
Overview
Explore the profile of Kouichi Tanonaka including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
81
Citations
711
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Marunouchi T, Matsumura K, Sato K, Takeuchi S, Murakami T, Tanonaka K
Biochem Pharmacol
. 2025 Feb;
233:116792.
PMID: 39894308
Statins, a class of dyslipidemic drugs known as HMG-CoA reductase inhibitors, have emerged as promising compounds for the treatment of chronic heart failure. Nevertheless, the precise mechanism remains to be...
2.
Marunouchi T, Onda S, Kurasawa M, Tanonaka K
Biol Pharm Bull
. 2024 Apr;
47(4):809-817.
PMID: 38583954
Several reports assume that myocardial necroptotic cell death is induced during the development of chronic heart failure. Although it is well accepted that angiotensin II induces apoptotic cell death of...
3.
Marunouchi T, Matsumura K, Fuji E, Iwamoto A, Tanonaka K
Pharmacology
. 2023 Nov;
109(1):43-51.
PMID: 38016432
Introduction: There is still no effective treatment for heart failure with preserved left ventricular ejection fraction (HFpEF), and therapies to improve prognosis are urgently needed. Clinical studies in patients with...
4.
Marunouchi T, Iguchi A, Shindo A, Shimbo N, Yano E, Tanonaka K
Biochem Pharmacol
. 2023 Apr;
212:115547.
PMID: 37054848
The NLR family pyrin domain containing 3 (NLRP3) inflammasome matures interleukin (IL)-1β and induces inflammation. The molecular chaperone heat shock protein 90 (Hsp90) is known to regulate the formation of...
5.
Marunouchi T, Fujita K, Takahashi K, Namiki S, Kyo L, Uchida M, et al.
J Pharmacol Sci
. 2022 Dec;
151(1):17-27.
PMID: 36522119
Hsp90 is a molecular chaperone that contributes to the activation and stabilization of client proteins. In our previous studies, we found that inhibition of Hsp90 delayed cardiac remodeling during the...
6.
Marunouchi T, Ito T, Onda S, Kyo L, Takahashi K, Uchida M, et al.
J Pharmacol Sci
. 2021 Aug;
147(2):192-199.
PMID: 34384567
In a previous study, we suggested that the Hsp90 inhibitor 17-AAG prevents cardiac dysfunction in the failing heart following myocardial infarction in rats. Although it is assumed that the RIP1/RIP3/MLKL...
7.
Marunouchi T, Nakashima M, Ebitani S, Umezu S, Karasawa K, Yano E, et al.
J Cardiovasc Pharmacol
. 2021 May;
77(6):822-829.
PMID: 34016843
In the previous study, we showed that an Hsp90 inhibitor, 17-(allylamino)-17-demethoxygeldanamycin (17-AAG), attenuates hypertrophic remodeling of cardiomyocytes during the development of heart failure. In this present study, we investigated the...
8.
Marunouchi T, Nishiumi C, Iinuma S, Yano E, Tanonaka K
Eur J Pharmacol
. 2021 Feb;
898:173987.
PMID: 33640405
Necroptosis is a programmed form of necrotic cell death. Necroptosis is regulated by the necroptosis-regulating proteins including receptor-interacting protein (RIP) 1, RIP3, and mixed lineage kinase domain-like (MLKL), the activities...
9.
Marunouchi T, Sasaki K, Yano E, Tanonaka K
J Pharmacol Sci
. 2019 Aug;
140(3):236-241.
PMID: 31375326
The cardiosphere-derived cell (CDC) is one of the candidate cells used for cardiac regenerative therapy. Cardiospheres are mixture of cells including c-Kit cells, stem cell antigen (Sca)-1 cells, and other...
10.
Nagata S, Marunouchi T, Tanonaka K
Biol Pharm Bull
. 2019 Jan;
42(3):453-461.
PMID: 30626801
Protein quality control (PQC) in the heart plays an important role to maintain cellular protein homeostasis. Impairment of PQC may cause the development of heart failure. It is well known...